2022 Yearbook/Report of Global Vaccine Partnership Terms and Agreements: Agreement Trends, Players and Financials Since 2014 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The report “Global Vaccine Partnering Terms and Agreements 2014-2022: Deal Trends, Players and Financials” has been added to from ResearchAndMarkets.com offer.

This report contains a comprehensive list of all vaccine partnership agreements announced since January 2014, including financial terms when available, including over 1100 links to online agreement records of partnership agreements on the actual vaccines, as disclosed by the parties to the agreement. In addition, when available, the records include contract documents as submitted to the Securities Exchange Commission by the companies and their partners.

  • Trends in Vaccine and Adjuvant Partnership Agreements

  • Structure of the partnership agreement

  • Partnership contract documents

  • Best deals by value

  • Most Active Negotiators

  • Average contract terms for vaccines

The report introduces readers to vaccine deal trends, key players, and key deal values, helping to understand how, why, and under what terms companies are currently entering into vaccine partnership deals.

The report presents the average values ​​of vaccine contract financial terms, where applicable, a listing by global aggregate value, upfront payments, milestones and royalties allowing readers to analyze and compare the value of ongoing contracts.

The middle section of the report explores leaders in the field of vaccine partnerships; key deal values ​​and key players are reported, allowing readers to see who is succeeding in this growing market. This chapter also examines the contributions of the world’s largest pharmaceutical and biotechnology companies in terms of closed deals.

One of the main highlights of the report is that over 1,100 online transaction records of actual vaccine transactions, as disclosed by the parties to the transaction, are included near the end of the report in an easy directory format. to consult. Each agreement is linked via Weblink to an online version and all these agreements are organized by AZ company, stage of development at signing, type of agreement (collaborative R&D, co-promotion, license, etc.), specific therapy and concentration technological. In addition, the report includes the actual contract documents, when available, as submitted to the Securities Exchange Commission by the companies and their business partners.

Contract documents provide the answers to many questions about a potential partner’s flexibility on a wide range of important issues, many of which will significantly impact each party’s ability to derive value from the agreement.

Finally, the report concludes by examining the future of the vaccine partnership. With so many innovators looking for the next big thing in the field, the report picks out companies to watch that are expected to become big in the field based on their current deal and financial trends.

Throughout the report, various tables, figures and graphs are incorporated to illustrate trends and partnership activities in the field of vaccines.

By the end of the report, potential negotiators will have gained an in-depth understanding of the vaccines market partnership landscape and will be familiar with the values ​​and structures of the agreements signed within it.

Global Vaccine Partnership Terms and Agreements 2014-2022: Agreement Trends, Players and Finances include:

  • Trends in vaccine transactions in the biopharmaceutical industry since 2014

  • Access to master, initial, milestone and royalty data

  • Access to over 1100 vaccine contract documents

  • Main vaccine sales by value since 2014

  • Most active vaccine negotiators since 2014

  • Key Vaccine Partnership Resources

The available contracts are listed by:

  • A-Z company

  • Face value

  • Stage of development at signing

  • Offer component type

  • Therapeutic target

  • Specific type of technology

The analysis of the actual contractual agreements makes it possible to evaluate the following elements:

  • What specific vaccine rights are granted or optional?

  • What is actually granted by the agreement to the partner company?

  • What exclusivity is granted?

  • What is the payment structure for the transaction?

  • How are sales and payments audited?

  • What is the duration of the agreement?

  • How are the main terms of the agreement defined?

  • How are IPRs managed and owned?

  • Who is responsible for marketing?

  • Who is responsible for development, supply and manufacturing?

  • How are confidentiality and publication managed?

  • How to settle disputes?

  • Under what conditions can the agreement be terminated?

  • What happens if the owner changes?

  • What sub-licensing and sub-contracting arrangements have been agreed upon?

  • What boilerplate clauses does the company insist on?

  • What boilerplate clauses seem to differ from one partner to another or from one type of transaction to another?

  • What jurisdiction does the company insist on for contract law?

Main topics covered:


Chapter 1 Introduction

Chapter 2 – Trends in Vaccine Trading

2.1. Introduction

2.2. Vaccines team up over the years

2.3. Most Active Vaccine Negotiators

2.4. Vaccine partnerships by agreement type

2.5. Vaccine partnerships by therapeutic area

2.6. Terms of Agreement for Vaccine Partnership

2.6.1 Core values ​​of the vaccine partnership

2.6.2 Vaccines process upfront payments

2.6.3 Milestone payments for the vaccine agreement

2.6.4 Royalty rates on vaccines

Chapter 3 – Major Vaccine Offerings

3.1. Introduction

3.2. Best Vaccine Deals by Value

Chapter 4 – The most active vaccine dealers

4.1. Introduction

4.2. Most Active Vaccine Negotiators

4.3. Profiles of the most active partner companies for vaccines

Chapter 5 – Vaccine contract negotiation directory

5.1. Introduction

5.2. Vaccine contract negotiation directory

Chapter 6 – Negotiation of vaccines by type of technology


Annex 1 – Vaccine offers by company AZ

Annex 2 – Vaccine offers by stage of development

  • Discovery

  • Preclinical

  • Phase I

  • Stage II

  • Phase III

  • Regulatory

  • Marketed

  • Formulation

Annex 3 – Vaccine transactions by type of transaction

  • Purchase of assets

  • Assignment

  • Big Pharma Licensing

  • Co-development

  • Collaborative R&D

  • Co-market

  • Co-promotion


  • Cross Licensing

  • Development

  • Distribution

  • Purchase of shares

  • Evaluation

  • To agree

  • joint venture

  • Licence

  • Manufacturing

  • Marketing

  • Transfer of material

  • Option

  • Promotion

  • To research

  • Rules

  • Dilute

  • Licensed

  • Provide

  • Technology transfer

  • Termination

Annex 4 – Vaccine offers by therapeutic area

  • Anesthetics

  • Cardiovascular

  • Central nervous system

  • Dental

  • gastrointestinal

  • Hematology

  • Immunology

  • Infectious

  • Metabolic

  • Musculoskeletal

  • Oncology

  • Ophthalmic

  • Orphan disease

  • Pediatrics

  • Psychiatry

  • Respiratory

Annex 5 – Definitions of types of transactions

Annex 6 – Further reading on dealmaking

Companies cited

  • 2A

  • 3d drugs

  • 3SBio

  • 4D Pharma

  • A*STAR’ Institute of Molecular and Cellular Biology

  • ABEC


  • AGC Organic Products

  • Organic Agenus

  • Agilvax

  • AIM ImmunoTech

  • Akers Biosciences

  • Amyris

  • Analytical biochemistry laboratories

  • AnGès MG

  • Anixa Biosciences

  • Battle

  • Batu Biologics

  • CTC Research

  • Celldex therapeutics

  • Cellular Biomedicine

  • Celonic

  • Diavax Biosciences

  • Diaxonhit

  • DNA script

  • DNAtrix

  • Dr. Reddy’s Laboratories

  • Frederick National Cancer Research Laboratory

  • Fred Hutchinson Cancer Research Center

  • Fuji film

  • GISCAD Foundation

  • GlaxoSmithKline

  • Hefei Sageland Biotechnology

  • Helmholtz Zentrum Munchen

  • MinervaX

  • Recipharm

  • Sanofi

  • Wyss Institute

  • Xenetic Biosciences

  • XstalBio

  • Y-Organic

  • Therapeutic Y-mAbs

  • Yale University

  • Yamaguchi University

  • Yisheng Biopharma

  • Zenoaq

  • Zoetis

  • Zolovax

  • Zuellig Pharma China

  • Zydus Cadila

  • ZYUS Life Sciences

For more information about this report visit https://www.researchandmarkets.com/r/au7tp6

Comments are closed.